GlycoEra
GlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications. Founded by a highly experienced team of glycoengineering leaders, the company is based in Schlieren, Switzerland.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.glycoera.com
Related News
GlycoEra AG expands Board of Directors and appoints Georges Gemayel, Ph.D., as Chair
GlycoEra AG announces appointment of Tanmoy Ganguly, Ph.D., as Chief Scientific Officer
GlycoEra AG appoints Ganesh V. Kaundinya as President and Chief Executive Officer
GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.